Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome

Sponsor
Beni-Suef University
Study ID
NCT05965908
Phase
PHASE3
Status
Completed

Conditions

  • Polycystic Ovary

Eligibility Criteria

Sex
FEMALE
Age
20 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    glucagon-like peptide 1 receptor agonist
  • Metformin — DRUG
    biguanide antihyperglycemic

Study Details

The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and liraglutide in infertile women with PCOs.

Key Dates

Start date
Jan 30, 2024
Status verified
Mar 2026
Primary completion
Mar 30, 2025
Completion
Mar 30, 2025

Study Design

Enrollment
150 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: liraglutide
    Saxenda® starting dose is 0.6 mg per day for 1 week.1. Patients increase the dose by 0.6 mg each week until the full maintenance dose of 3 mg is reached
  • Active Comparator: metformin
    the patient is given Glucophage 1000 mg tab once daily after lunch for 1month
  • No Intervention: control
    not given any drug

Primary Outcome Measure

Body weight loss [ Time Frame: 1 months ]

Related coverage on Hipa.ai